Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorZhujiang Hospital
About this trial
The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy. At the same time, to explore the relationship among the two methods of predicting recurrence of hepatocellular carcinoma, postoperative adjuvant therapy and postoperative recurrence, this study further confirmed the effectiveness of ctDNA-MRD longitudinal monitoring model in monitoring postoperative recurrence of hepatocellular carcinoma and guiding treatment.
Eligibility criteria
Qualifiers
Male or female patients aged 18-75 years;
Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0/ stage A/stage B, eligible for radical surgery;
ECOG physical status score is 0-1;
Child-Pugh score is 5-6 points (Level A);
Disqualifiers
Patient can't provide blood samples for ctDNA testing;
Patient with two or more types of tumors at the same time;
Non-primary liver lesions;
Pregnant or lactating women;
Trial design
Treatments tested in this trial
- circulating tumor cell DNA detection
Treatment groups
152 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov